Dose and schedule modification are required for long-term continuation of sunitinib in Japanese patients with advanced pancreatic neuroendocrine tumors

作者： Lingaku Lee , Tetsuhide Ito , Hisato Igarashi , Masami Miki , Nao Fujimori

关键词: Term (time) 、 Internal medicine 、 Medicine 、 Schedule 、 Oncology 、 Neuroendocrine tumors 、 Sunitinib 、 Pharmacology toxicology

摘要: Purpose This study aimed to clarify the efficacy and safety of sunitinib in Japanese patients with pancreatic neuroendocrine tumors (PNET), especially by focusing on dose schedule modification.

参考文章(32)

Fred T Bosman, Fatima Carneiro, Ralph H Hruban, Neil D Theise, WHO Classification of Tumours of the Digestive System WHO classification of tumours of the digestive system.. ,(2010)

J.L. Lee, M.K. Kim, I. Park, J.-H. Ahn, D.H. Lee, H.M. Ryoo, C. Song, B. Hong, J.H. Hong, H. Ahn, RandomizEd phase II trial of Sunitinib four weeks on and two weeks off versus Two weeks on and One week off in metastatic clear-cell type REnal cell carcinoma: RESTORE trial Annals of Oncology. ,vol. 26, pp. 2300- 2305 ,(2015) , 10.1093/ANNONC/MDV357

Hideyuki Akaza, Seiji Naito, Naomi Ueno, Kouji Aoki, Hiroyuki Houzawa, Susan Pitman Lowenthal, Sang-Yoon Lee, Real-world use of sunitinib in Japanese patients with advanced renal cell carcinoma: efficacy, safety and biomarker analyses in 1689 consecutive patients Japanese Journal of Clinical Oncology. ,vol. 45, pp. 576- 583 ,(2015) , 10.1093/JJCO/HYV045

Tetsuhide Ito, Hisato Igarashi, Kazuhiko Nakamura, Hironobu Sasano, Takuji Okusaka, Koji Takano, Izumi Komoto, Masao Tanaka, Masayuki Imamura, Robert T. Jensen, Ryoichi Takayanagi, Akira Shimatsu, Epidemiological trends of pancreatic and gastrointestinal neuroendocrine tumors in Japan: a nationwide survey analysis Journal of Gastroenterology. ,vol. 50, pp. 58- 64 ,(2015) , 10.1007/S00535-014-0934-2

Hyo Song Kim, Min Hee Hong, Kiyeol Kim, Sang-Joon Shin, Joong-Bae Ahn, Hei Chul Jeung, Hyun Cheol Chung, Youngil Koh, Se-Hoon Lee, Yung-Jue Bang, Sun Young Rha, None, Sunitinib for Asian patients with advanced renal cell carcinoma: a comparable efficacy with different toxicity profiles. Oncology. ,vol. 80, pp. 395- 405 ,(2011) , 10.1159/000330361

Yi Ling Teo, Xiu Ping Chue, Noan Minh Chau, Min-Han Tan, Ravindran Kanesvaran, Hwee Lin Wee, Han Kiat Ho, Alexandre Chan, Association of drug exposure with toxicity and clinical response in metastatic renal cell carcinoma patients receiving an attenuated dosing regimen of sunitinib. Targeted Oncology. ,vol. 10, pp. 429- 437 ,(2015) , 10.1007/S11523-014-0349-2

Yasuyoshi Ishiwata, Yutaka Takahashi, Hiromitsu Takahashi, Kazutaka Saito, Yasuhisa Fujii, Kazunori Kihara, Masato Yasuhara, Masashi Nagata, Pharmacokinetic-pharmacodynamic analysis of sunitinib-induced thrombocytopenia in Japanese patients with renal cell carcinoma Biological & Pharmaceutical Bulletin. ,vol. 38, pp. 402- 410 ,(2015) , 10.1248/BPB.B14-00636

S. George, J.Y. Blay, P.G. Casali, A. Le Cesne, P. Stephenson, S.E. DePrimo, C.S. Harmon, C.N.J. Law, J.A. Morgan, I. Ray-Coquard, V. Tassell, D.P. Cohen, G.D. Demetri, Clinical evaluation of continuous daily dosing of sunitinib malate in patients with advanced gastrointestinal stromal tumour after imatinib failure. European Journal of Cancer. ,vol. 45, pp. 1959- 1968 ,(2009) , 10.1016/J.EJCA.2009.02.011

Tetsuhide Ito, Takuji Okusaka, Toshirou Nishida, Kenji Yamao, Hisato Igarashi, Chigusa Morizane, Shunsuke Kondo, Nobumasa Mizuno, Kazuo Hara, Akira Sawaki, Satoshi Hashigaki, Nobuyuki Kimura, Mami Murakami, Emiko Ohki, Richard C. Chao, Masayuki Imamura, Phase II study of sunitinib in Japanese patients with unresectable or metastatic, well-differentiated pancreatic neuroendocrine tumor Investigational New Drugs. ,vol. 31, pp. 1265- 1274 ,(2013) , 10.1007/S10637-012-9910-Y

10.

S Novello, G V Scagliotti, R Rosell, M A Socinski, J Brahmer, J Atkins, C Pallares, R Burgess, L Tye, P Selaru, E Wang, R Chao, R Govindan, Phase II study of continuous daily sunitinib dosing in patients with previously treated advanced non-small cell lung cancer British Journal of Cancer. ,vol. 101, pp. 1543- 1548 ,(2009) , 10.1038/SJ.BJC.6605346

Dose and schedule modification are required for long-term continuation of sunitinib in Japanese patients with advanced pancreatic neuroendocrine tumors

来源期刊

我的账户

Dose and schedule modification are required for long-term continuation of sunitinib in Japanese patients with advanced pancreatic neuroendocrine tumors

来源期刊

相似文章 7

Sunitinib shrinks NET-G3 pancreatic neuroendocrine neoplasms.

A case of advanced pancreatic neuroendocrine tumor in which octreotide long-acting repeatable was effective after failure of everolimus and sunitinib.

Real-world use of sunitinib in Japanese patients with pancreatic neuroendocrine tumors: results from a post-marketing surveillance study

Efficacy and safety of sunitinib in Japanese patients with progressive, advanced/metastatic, well-differentiated, unresectable pancreatic neuroendocrine tumors: final analyses from a Phase II study

Perspective of neo-adjuvant/conversion and adjuvant therapy for pancreatic neuroendocrine tumors

Oral intake of royal jelly improves anti‑cancer effects and suppresses adverse events of molecular targeted therapy by regulating TNF‑α and TGF‑β in renal cell carcinoma: A preliminary study based on a randomized double‑blind clinical trial

Update in clinical management for gallbladder neuroendocrine carcinoma.

我的账户